PE20231678A1 - Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico - Google Patents

Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico

Info

Publication number
PE20231678A1
PE20231678A1 PE2023001760A PE2023001760A PE20231678A1 PE 20231678 A1 PE20231678 A1 PE 20231678A1 PE 2023001760 A PE2023001760 A PE 2023001760A PE 2023001760 A PE2023001760 A PE 2023001760A PE 20231678 A1 PE20231678 A1 PE 20231678A1
Authority
PE
Peru
Prior art keywords
seq
lupus erythematosus
cdr1
cdr3
cdr2
Prior art date
Application number
PE2023001760A
Other languages
English (en)
Spanish (es)
Inventor
Francois Gaudreault
Himanshu Naik
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PE20231678A1 publication Critical patent/PE20231678A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2023001760A 2020-12-03 2021-12-03 Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico PE20231678A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121194P 2020-12-03 2020-12-03
PCT/US2021/061764 WO2022120144A1 (en) 2020-12-03 2021-12-03 Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
PE20231678A1 true PE20231678A1 (es) 2023-10-19

Family

ID=79024222

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001760A PE20231678A1 (es) 2020-12-03 2021-12-03 Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico

Country Status (15)

Country Link
US (1) US20240018246A1 (https=)
EP (1) EP4255392A1 (https=)
JP (1) JP2024501430A (https=)
KR (1) KR20230119664A (https=)
CN (1) CN116963716A (https=)
AR (1) AR124247A1 (https=)
AU (1) AU2021391803A1 (https=)
CA (1) CA3203971A1 (https=)
CL (1) CL2023001562A1 (https=)
CO (1) CO2023008272A2 (https=)
IL (1) IL303279A (https=)
MX (1) MX2023006474A (https=)
PE (1) PE20231678A1 (https=)
TW (1) TW202222829A (https=)
WO (1) WO2022120144A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1454215B (zh) * 1999-11-15 2013-01-02 米勒腾尼生物技术有限公司 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞
AU2013359419B2 (en) * 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
CN109475623B (zh) 2016-04-28 2023-05-26 比奥根Ma公司 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案

Also Published As

Publication number Publication date
MX2023006474A (es) 2023-08-16
KR20230119664A (ko) 2023-08-16
AU2021391803A1 (en) 2023-07-06
CL2023001562A1 (es) 2023-12-15
CA3203971A1 (en) 2022-06-09
CO2023008272A2 (es) 2023-09-29
AR124247A1 (es) 2023-03-01
EP4255392A1 (en) 2023-10-11
AU2021391803A9 (en) 2024-09-26
WO2022120144A1 (en) 2022-06-09
US20240018246A1 (en) 2024-01-18
CN116963716A (zh) 2023-10-27
JP2024501430A (ja) 2024-01-12
TW202222829A (zh) 2022-06-16
IL303279A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US20260098089A1 (en) Antagonist anti-cd7 antibodies
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
CA2549652C (en) Cd40 antibody formulation and methods
US9828425B2 (en) Anti-ILT5 antibodies and ILT5-binding antibody fragments
AR113777A1 (es) Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos
JP7606706B2 (ja) ヒトネクチン-2に特異的な抗体
KR20220082097A (ko) 방사선 치료와 조합된 pd-1 및 pd-l1에 대한 길항제를 이용하는 암 치료 방법
CN116640214A (zh) 分离抗体及其应用
US20220396623A1 (en) Uses of anti-icos antibodies
AR126614A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
TW202144420A (zh) 一種免疫細胞啟動劑的開發及應用
SG194362A1 (en) Composition for treating disease
AU2020372646A1 (en) Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
PE20231678A1 (es) Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico
KR20220034807A (ko) Cd38에 대해 특이성을 갖는 항체 및 이의 용도
US20240190964A1 (en) Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
WO2021259902A1 (en) Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
JP2022538688A (ja) IGSF11(VSIG3)のIgC2に結合する抗体及びその使用
CA3035807A1 (en) Irradiation treatment of neurological sensations by photoablation
US20250340641A1 (en) Uses of anti-icos antibodies
IL321673A (en) LILRB1 and LILRB2 antigen-binding cross-specific proteins, their combinations and uses
JP2025504020A (ja) Pd-1アゴニストであるプログラム細胞死タンパク質1に対する抗体
Chauchet et al. 265 CD47xPD-L1 bispecific antibodies for cancer therapy
Sun et al. Rifampicin-dependent antibodies target glycoprotein IIb/IIIa and cause clearance of human platelets in NOD/SCID mice.